SAN DIEGO, June 7, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer, announced today that the Society of Nuclear Medicine and Molecular Imaging (SNMMI) has chosen MabVax's immunoPET imaging agent, MVT-2163, for a podium presentation and a poster presentation at the upcoming annual meeting to be held in Denver, CO on June 10-14, 2017.
The poster will be presented by Joseph O'Donoghue, Ph.D., Associate Attending Physicist, Department of Medical Physics at Memorial Sloan Kettering Cancer Center.
Poster Title: Biodistribution and radiation dose estimates for 89Zr-DFO-HuMab-5B1 (MVT-2163) in CA19-9 positive cancer: first-in-man results
Location: Hall C in the Colorado Convention Center, Denver Colorado
Session Date: Sunday, June 11, 2017
Time: 7:00 PM to 8:30 PM (CDT)
The podium presentation will be given by Lars Guenter Christian Lohrmann, M.D., Assistant Member and Assistant Attending Radiologist at Memorial Sloan Kettering Cancer Center, and lead investigator in the MVT-2163 Phase 1 clinical trial.
Title of Presentation: First-in-Human Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) PET/CT imaging with and without HuMab-5B1 (MVT-5873) in patients with pancreatic cancer and other CA 19-9 positive malignancies
Location: Room 601 in the Colorado Convention Center, Denver Colorado
Session Date: Tuesday, June 13, 2017
Time: 8:10 AM (CDT)
These presentations will discuss the results of the Company's Phase 1a dose-escalation and safety trial conducted in 12 patients with advanced pancreatic cancer. Both presentations will include PET scan images illustrating the utility of this novel immunoPET imaging agent and its potential role in preoperative staging of patients with pancreatic cancer.
About MabVax Therapeutics Holdings, Inc.
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. Our lead antibody is directed at an antigen target expressed on more than 90% of pancreatic cancers and a significant amount of other GI and lung cancers, making the antibody potentially broadly applicable to a wide variety of patients suffering from difficult to treat cancers. With our collaborators including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon, Honor Health and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase I clinical studies, and demonstrated early safety, specificity for the target and a potential efficacy signal. Additionally, our Phase I clinical study of our radioimmunotherapy product designated as MVT-1075 has commenced patient enrollment. For additional information, please visit the Company's website, www.mabvax.com.
Forward Looking Statements:
This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to presentations at the SNMMI Annual Meeting. We have no assurance that all the product development pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended and supplemented from time to time and the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mabvax-therapeutics-immunopet-imaging-agent-mvt-2163-to-be-featured-in-two-presentations-at-the-2017-snmmi-annual-meeting-300469920.html
SOURCE MabVax Therapeutics Holdings, Inc.